WANYI SCIENCE(SH:688600) Huachuang Securities·2026-03-01 00:25Investment Rating - The report maintains a "Strong Buy" rating for the company, indicating an expectation to outperform the benchmark index by over 20% in the next six months [6][22]. Core Insights - The company achieved a significant year-on-year increase in net profit attributable to shareholders of 295.5% in 2025, despite a slight decline in total revenue of 4.1% [6][7]. - The growth in profitability is attributed to improved operational efficiency, product structure optimization, and increased government subsidies [6][7]. - The company is positioned to benefit from the expanding controlled nuclear fusion sector, which is expected to enter a capital expenditure expansion cycle from 2025 to 2028 [6][7]. - There is a substantial market opportunity for domestic laboratory instruments, with a current low penetration rate of domestic products in a market worth over 50 billion [6][7]. - The medical instruments segment has shown promising developments, particularly in minimally invasive surgical instruments and high-value consumables, which are expected to become a new growth driver for the company [6][7]. Financial Summary - Total revenue is projected to decline from 740 million in 2024 to 710 million in 2025, before rebounding to 1,006 million in 2026 and 1,229 million in 2027, reflecting a compound annual growth rate of approximately 41% from 2026 to 2028 [2][6]. - Net profit attributable to shareholders is expected to rise from 14 million in 2024 to 57 million in 2025, and further to 103 million in 2026 and 147 million in 2027, with corresponding growth rates of 295.5% and 80.5% [2][6]. - The company's earnings per share (EPS) is forecasted to increase from 0.11 yuan in 2024 to 0.42 yuan in 2025, reaching 0.76 yuan in 2026 and 1.09 yuan in 2027 [2][6]. - The target price for the company's stock is set at 37.4 yuan, representing a 29% upside from the current price of 28.91 yuan [2][6].